UPS Healthcare and THREAD Partner to Deliver DCT Platform
UPS Healthcare's clinical trial logistics unit, Marken, and THREAD, a decentralized clinical trial technology provider, announced a partnership to bring the first ever, unified, decentralized clinical trial solution into patients' homes. The combined offering brings together THREAD's digital platform and Marken's Home Healthcare and clinical trial logistics services to create a single workflow for clients and patients.The platform includes eConsent, eCOA, telehealth Virtual Visits, patient engagement and eSource, along with other features.
The new technology platform further expands Marken's patient-centric solution portfolio, which includes Home Healthcare (HHC), Clinical Trial Logistics and Direct-to-Patient/Direct-from-Patient distribution services.
For more information, click here.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
